I am working for a drug for which, I can not share name but having a Benzothiapine ring. Oxidative metabolite i.e. sulfoxide of drug is form in-vivo on dosing of the drug formulation. I am getting stuck where, this sulfoxide metabolite is readily converted to sulphide (back to drug substance) by reduction through reductase enzymes and interfering to free-drug during detection in LCMS analysis.

Can any one suggest the way out i.e. any reductase inhibitor that can work or derivetization of sulfoxide to prevent conversion to free-drug.

More Nitesh Patel's questions See All
Similar questions and discussions